Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvation Bio Inc.NUVB · Entity 4384 | CHIEF SCIENTIFIC OFFICER | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvation Bio Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-19 · Exercise / conversion · Acquired 100,000 · Balance 100,000 Row 2 · 2026-08-19 · Sale · Disposed 100,000 · Balance 0 F1: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.02 to $7.21. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2034-02-27 | Direct | 400,000 |
Reported balance
After 2026-08-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-19 · Exercise / conversion · Disposed 100,000 · Balance 400,000 F3: Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.02 to $7.21. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Radius Health, Inc.
Report date December 31, 2018 · Filed February 13, 2019
Section 16 reporting ended · disclosed 2019-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,173 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,173 F1: Includes 666 shares that were acquired as follows: (i) 287 shares acquired under the Issuer's employee stock purchase plan on February 28, 2018; and (ii) 379 shares acquired under the Issuer's employee stock purchase plan on August 31, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 666 shares that were acquired as follows: (i) 287 shares acquired under the Issuer's employee stock purchase plan on February 28, 2018; and (ii) 379 shares acquired under the Issuer's employee stock purchase plan on August 31, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 20:49 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001521111-26-000005 · form4-08212026_080836.xml · derivative · entry 3 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,000 Underlying: Class A Common Stock · 100,000 shares Expires 2034-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:49 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 100,000 | $7.09 | $709,240.00 |
DisclosureSEC source: 0001521111-26-000005 · form4-08212026_080836.xml · nonDerivative · entry 2 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.02 to $7.21. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:49 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 100,000 | $1.87 | $187,000.00 |
DisclosureSEC source: 0001521111-26-000005 · form4-08212026_080836.xml · nonDerivative · entry 1 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:57 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 748,130 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001521111-26-000003 · form4-03042026_120312.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 748,130 Underlying: Class A Common Stock · 748,130 shares Expires 2036-02-26 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001521111-25-000006 · form4-11242025_091137.xml · derivative · entry 6 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Class A Common Stock · 300,000 shares Expires 2033-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 69,051 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001521111-25-000006 · form4-11242025_091137.xml · derivative · entry 5 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,884 Underlying: Class A Common Stock · 69,051 shares Expires 2030-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 300,000 | $7.23 | $2,168,100.00 |
DisclosureSEC source: 0001521111-25-000006 · form4-11242025_091137.xml · nonDerivative · entry 4 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.15 to $7.43. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 300,000 | $1.94 | $582,000.00 |
DisclosureSEC source: 0001521111-25-000006 · form4-11242025_091137.xml · nonDerivative · entry 3 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 69,051 | $7.23 | $499,031.58 |
DisclosureSEC source: 0001521111-25-000006 · form4-11242025_091137.xml · nonDerivative · entry 2 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.15 to $7.43. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:09 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 69,051 | $1.74 | $120,148.74 |
DisclosureSEC source: 0001521111-25-000006 · form4-11242025_091137.xml · nonDerivative · entry 1 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 20:24 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001521111-25-000003 · form4-10292025_081026.xml · derivative · entry 3 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 298,935 Underlying: Class A Common Stock · 100,000 shares Expires 2030-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vest as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 20:24 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 100,000 | $5.02 | $502,460.00 |
DisclosureSEC source: 0001521111-25-000003 · form4-10292025_081026.xml · nonDerivative · entry 2 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares sold pursuant to a 10b5-1 plan dated June 24, 2024. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.08. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 20:24 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | Exercise / conversionClass A Common Stock | 100,000 | $1.74 | $174,000.00 |
DisclosureSEC source: 0001521111-25-000003 · form4-10292025_081026.xml · nonDerivative · entry 1 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:30 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001415889-25-006688 · form4-03042025_110338.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2025, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 21:33 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001415889-24-006294 · form4-03042024_090331.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2034-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:56 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001209191-23-014882 · doc4.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 21:16 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001209191-22-048151 · doc4.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Class A Common Stock · 400,000 shares Expires 2032-08-28 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:06 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001209191-22-014872 · doc4.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2032-02-27 F1 · derivative.exercise_date: Option vests as to 25% on the one year anniversary of 2/28/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:47 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $1.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-010334 · doc4.xml · derivative · entry 2 Hattersley Gary · CIK 0001521111 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F4 · derivative.exercise_date: Options vest as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:47 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantStock Option (Right to Buy) · Derivative | 398,935 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001209191-21-010334 · doc4.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,935 Underlying: Class A Common Stock · 398,935 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F3 · price: Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock. F2 · derivative.exercise_date: Options vest as to 20% on October 5, 2023, 20% on October 5, 2023 and 60% on October 5, 2025, subject to achievement of performance criteria. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 19:41 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $37.83 | $0.00 |
DisclosureSEC source: 0001209191-18-010550 · doc4.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-02-12 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 13, 2019 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 16:27 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-17-013258 · doc4.xml · derivative · entry 1 Hattersley Gary · CIK 0001521111 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-02-16 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 17, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.